{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["325(1)"],"submitter":["Wang X"],"pubmed_abstract":["<h4>Importance</h4>Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.<h4>Objective</h4>To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.<h4>Design, setting, and participants</h4>Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.<h4>Interventions</h4>Eligible patients were randomized 1:"],"journal":["JAMA"],"pagination":["50-58"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7729589"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial."],"pmcid":["PMC7729589"],"pubmed_authors":["Peng RJ","Li JB","Xue C","Guo Y","Huang H","He ZY","Shi W","Cai L","Lin Y","Bi XW","Jiang KK","Tang J","Zhao L","Wang XM","South China Breast Cancer Group (SCBCG)","An X","Wang X","Wang XY","Hua X","Huang JJ","Huang ZZ","Song CG","Zhang LH","Shi YX","Pang DM","Xu F","Su YH","Yuan ZY","Xia W","Hong RX","Liu XM","Chen QJ","Zhang AQ","Lin HX","Ke YL","Cao Y","Zeng J","Wang SS","Zhong YY"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.","description":"<h4>Importance</h4>Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.<h4>Objective</h4>To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.<h4>Design, setting, and participants</h4>Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.<h4>Interventions</h4>Eligible patients were randomized 1:","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-05-02T00:56:04.713Z","creation":"2022-02-10T14:19:36.576Z"},"accession":"S-EPMC7729589","cross_references":{"pubmed":["33300950"],"doi":["10.1001/jama.2020.23370"]}}